A Phase 1/2 interventional study of ITU512 and Placebo in Sickle Cell Disease, sponsored by Novartis Pharmaceuticals. Recruiting at 14 sites in 3 countries. Open to participants aged 12 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Anemia, Sickle Cell by Novartis — 3 open to participants now, 5 under way, 2 of them phase 3. Anemia, Sickle Cell · Novartis.
Among the 25 studies in Anemia, Sickle Cell by Novartis, this one is the 7th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 1/2, and was the 22nd registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →3 of the 25 studies in Anemia, Sickle Cell by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 2 more countries
Ages 12–100
Novartis Pharmaceuticals · Sites in United States, Belgium, Brazil and 8 more countries
Ages 6 mo–100 yrs
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 12 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 3 · Phase 4 2
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 161 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 135 across the 16 interventional studies, 337 across the 8 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Anemia, Sickle Cell by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).
This is a global, randomized, Phase I/II study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary food effect of single-agent ITU512 in adult healthy participants, and safety, tolerability, PK, PD, and efficacy of ITU512 in adolescent and adult patients with sickle cell disease (SCD). The study consists of a first-in-human Phase I study (Part 1) in healthy participants, and a Phase II study (Part 2) in patients with SCD.
Part 1 will comprise of Part 1A, Part 1B, and Part 1C. Part 2 will include Part 2A and 2B and may also include an extension part (Part 2C).
Key Inclusion Criteria:
Part 1 (Healthy participants)
Part 2 (Sickle Cell Disease)
- Male and female participants with a diagnosis of sickle cell disease
Key Exclusion Criteria:
Part 1 (Healthy participants)
Part 2 (Sickle Cell Disease)
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1A in healthy participants
Drug: ITU512 · Drug: Placebo
Part 1B in healthy participants
Drug: ITU512 · Drug: Placebo
Part 1C in healthy participants
Drug: ITU512
Part 2A in patients with sickle cell disease
Drug: ITU512 · Drug: Placebo
Part 2B in patients with sickle cell disease
Drug: ITU512 · Drug: Placebo
Optional extension in patients with sickle cell disease
Drug: ITU512
ITU512 is an investigational, oral, low molecular weight (LMW) compound.
An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.
Part 1A, Part 1B, Part 1C: Incidence of AEs and SAEs
Number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.
Time frame: Up to approximately 60 days
Part 1A, Part 1B , Part 1C: Dose discontinued due to AE
Number of participants with dose discontinuation due to AEs
Time frame: Up to 30 days
Part 2A, Part 2B: Incidence of AEs and SAEs
Number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.
Time frame: Up to 5 months
Part 2A, Part 2B: Dose interruptions and reductions
Number of participants with dose interruptions or reductions of ITU512
Time frame: Up to 4 months
Part 2A, Part 2B: Dose intensity
Dose intensity of ITU512 is computed as the ratio of actual cumulative dose received and actual duration of exposure
Time frame: Up to 4 months
Part 2B: Fetal hemoglobin (HbF)%
Assessment of fetal hemoglobin expression by measuring fetal hemoglobin (HbF)% by high-performance liquid chromatography (HPLC) assay
Time frame: Month 4
Part 1A, Part 1B: Area under the plasma concentration-time curve (AUC) of ITU512
Pharmacokinetic (PK) parameters calculated based on ITU512 plasma concentrations by non-compartmental methods
Time frame: From pre-dose up to 144 hours post-dose on Day 1 (Part 1A) and from pre-dose up to 24 hours post-dose on Day 1 and Day 10 (Part 1B)
Part 1A, Part 1B: Maximum plasma concentration (Cmax) of ITU512
PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods
Time frame: From pre-dose up to 144 hours post-dose on Day 1 (Part 1A) and from pre-dose up to 24 hours post-dose on Day 1 and Day 10 (Part 1B)
Part 1A, Part 1B: Time to maximum plasma concentration (Tmax) of ITU512
PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods
Time frame: From pre-dose up to 144 hours post-dose on Day 1 (Part 1A) and from pre-dose up to 24 hours post-dose on Day 1 and Day 10 (Part 1B)
Part 1A, Part 1B: Renal clearance (CLr)
PK parameters calculated based on ITU512 urine concentrations by non-compartmental methods. The renal clearance (CLr) may be determined based on AUC and amount of drug excreted into urine (Ae) available for the same time period.
Time frame: From pre-dose up to 48 hours post-dose on Day 1 (Part 1A) and from pre-dose up to 24 hours post-dose on Day 1 and Day 10 (Part 1B)
Part 2A, Part 2B: Plasma concentrations of ITU512
ITU512 concentration in plasma determined in non-placebo treated participants by a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method
Time frame: From pre-dose up to 4, 6 or 8 hours post-dose on Day 1 at Month 1 and Month 2
Part 2A, Part 2B: Urine concentrations of ITU512
ITU512 concentration in urine determined in non-placebo treated participants by a LC-MS/MS method
Time frame: From pre-dose up to 4 or 8 hours post-dose on Day 1 at Month 1
Part 2A: Fetal hemoglobin (HbF)%
Assessment of fetal hemoglobin expression by measuring fetal hemoglobin (HbF)% by HPLC assay
Time frame: Up to 4 months
Part 2A, Part 2B: Change from baseline in total hemoglobin (Hb)
Change from baseline in total hemoglobin (Hb) over time measured in blood samples
Time frame: Baseline, up to 4 months
Part 1A, Part 1B, Part 2A, Part 2B: Change from baseline in Fridericia- corrected Holter QT interval (QTcF)
Real-time 12-lead safety ECGs will be locally collected and evaluated. Change from baseline in QTcF with respect to PK parameters and/or ITU512 concentrations will be assessed
Time frame: Up to 4 months
Part 1C: Area under the plasma concentration-time curve from time 0 up to the time of the last quantifiable concentration (AUClast) of ITU512
PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods
Time frame: From pre-dose up to 144 hours post-dose
Part 1C: Area under the plasma concentration-time curve from time 0 up to infinity (AUCinf) of ITU512
PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods
Time frame: From pre-dose up to 144 hours post-dose
Part 1C: Maximum plasma concentration (Cmax) of ITU512
PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods
Time frame: From pre-dose up to 144 hours post-dose
Part 1C: Time to maximum plasma concentration (Tmax) of ITU512
PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods
Time frame: From pre-dose up to 144 hours post-dose
Not enrolling at this site.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for May 2028, 44 months after the start.
Of 37 phase 1/2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 222. This study's planned 44 months is below that.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2030 → May 2030, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.